HEMLIBRA® is now approved for hemophilia A with FVIII inhibitors

Indication

HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.

HEMLIBRA Webcast

Stay up-to-date with informative webcast events

Mechanism of Action

How HEMLIBRA may work in patients with hemophilia A with FVIII inhibitors